If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
158.20    1.00 (0.64%)
Bid:
157.60
Ask:
157.80
Spread: 0.20 (0.127%)
Market Cap: £903.28m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading update

14 Jan 2020 07:00

RNS Number : 6681Z
Elementis PLC
14 January 2020
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No.596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Elementis plc

14 January 2020

Trading Update

 

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues the following trading update in advance of its full year results for the 12 months to 31 December 2019, which are scheduled to be announced on 4 March 2020.

Business performance

Trading in the final quarter of the year has been somewhat subdued and as a result adjusted operating profit for 2019 is anticipated to be $122-124m.

·; Personal Care had a mixed end to the year with continued solid performance in cosmetics and ongoing competitive pressures in AP Actives.

 

·; In Coatings, demand conditions were in line with expectations and operating margins remained resilient supported by new business wins, cost savings delivery and price/mix improvements.

 

·; In Talc, performance was in line with expectations with solid industrial talc demand driven by good momentum in coatings and technical ceramics, more than offsetting continued demand weakness in long life plastics. Second half performance materially improved driven by new business, cost synergies and nickel sales phasing.

 

·; In Chromium, a weak demand environment and lower market prices resulted in weaker than expected performance. This was particularly acute in the rest of the world, whereas margins in North America have remained robust.

 

·; Energy performance was weaker than expected due to a further slowdown in North American drilling activity, with the Q4 rig count down approximately 25% on the prior year period.

 

 

Cash Conversion

In 2019, our operating cash conversion* is expected to be in line with our medium term performance objective of at least 90%. This has been driven by disciplined capital expenditure and sustainable working capital reduction. As a result, net debt for the year is anticipated to be approximately $465m, representing around 2.8x net debt to EBITDA**.

Financial deleveraging remains a key focus. The execution of our medium term innovation, growth and efficiency priorities combined with strong cash generation will drive a clear deleveraging profile.

Paul Waterman, CEO, said,

"Our overall performance in 2019 has been negatively impacted by a challenging market backdrop as the more cyclically exposed parts of the portfolio like Chromium and Energy have deteriorated through H2. However, as outlined at the recent Capital Markets Day, our priorities going forward are clear. We remain committed to delivering our medium term Group performance objectives of a 17% operating profit margin, operating cash conversion of at least 90% per annum and financial leverage of under 1.5x EBITDA, with further reduction thereafter."

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

David Allchurch

 

Notes

*Defined as (Adjusted EBITDA - capex - working capital change) / adjusted operating profit

** Defined on a pre-IFRS16 basis

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGZGMMMFKGGZZ
Date   Source Headline
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.